Inflammation in atherosclerotic cardiovascular disease: From diagnosis to treatment
Why the study?
Despite guidelines recommending low-dose colchicine for secondary prevention in ASCVD patients with residual inflammatory risk, clinical adoption remains limited.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports exploration of anti-inflammatory add-ons to lipid therapy; leaves open clinical adoption pending randomized evidence.
Structured PICO
P
Population
Patients with prevalent atherosclerotic cardiovascular disease (ASCVD) with residual inflammatory risk
I
Intervention
Anti-inflammatory therapies (e.g., low-dose colchicine 0.5 mg daily, ziltivekimab) and hsCRP screening
Integrating anti-inflammatory interventions with aggressive lipid-modifying therapy in secondary prevention may further reduce the burden of ASCVD.
Cite This Study
Arnold et al. (2025) studied this question.